The ASAM State of the Art Course in Addiction Medicine 2016

The ASAM State of the Art Course in Addiction Medicine 2016 course video recordings.

This course is designed specifically for physicians and health care professionals seeking an advanced level of knowledge about breakthroughs in the field and will include:

  • Presentations focused on scientific advances and emerging evidence in addiction medicine
  • Sessions organized around ten topics that translate into clinically useful knowledge
  • Special addresses by directors of federal agencies including SAMHSA, NIDA, NIAAA
  • Concise presentations delving into understanding, preventing, diagnosing and treating addiction and co-occurring medical and psychiatric disorders
  • Evaluation and Certificate - 2016 State of the Art

    Contains 2 Component(s), Medical Credits Offered

    CME Evaluation for the ASAM State of the Art Course.

    Complete the course evaluation first and then claim credits. Attendees should claim only the credit commensurate with the extent of their participation in the activity.

  • Prescription Opioids: Misuse, Consequences and Countermeasures (2.25 CME)

    Contains 7 Component(s), Medical Credits Offered

    Session 1 from The ASAM State of the Art Course in Addiction Medicine contains 4 separate presentations on prescription opioids.

    Explore the extent of the current prescription opioid epidemic, the current transition to heroin, prescribing guidelines for opioid therapy for chronic pain, the evidence base for the risk/benefit of opioids for treating chronic pain, the use of agonist medication for medication assisted withdrawal, management of Opioid Use Disorder in pregnant women and maternal, fetal, neonatal and child outcomes associated with opioid agonist therapy.

    Theodore J. Cicero

    PhD

    Professor, Vice Chairman for Research

    Washington University School of Medicine in St. Louis

    Debra Houry

    MD, MPH

    Debra Houry, MD, MPH, is the Director of the National Center for Injury Prevention and Control (NCIPC) at CDC. In this role, Dr. Houry leads innovative research and science-based programs to prevent injuries and violence and to reduce their consequences. She joined the CDC in October 2014. She has previously served as Vice-Chair and Associate Professor in the Department of Emergency Medicine at Emory University School of Medicine and as Associate Professor in the Departments of Behavioral Science and Health Education and in Environmental Health at the Rollins School of Public Health. Dr. Houry also served as an Attending Physician at Emory University Hospital and Grady Memorial Hospital and as the Director of Emory Center for Injury Control. Her prior research has focused on injury and violence prevention in addition to the interface between emergency medicine and public health, and the utility of preventative health interventions and screening for high-risk health behaviors. She has received several national awards for her work in the field of injury and violence prevention. Dr. Houry received the first Linda Saltzman Memorial Intimate Partner Violence Researcher Award from the Institute on Violence, Abuse, and Trauma and the Academy of Women in Academic Emergency Medicine's Researcher Award. She is past president of the Society for Academic Emergency Medicine, the Society for Advancement of Violence and Injury Research, and Emory University Senate. Dr. Houry has served on numerous other boards and committees within the field of injury and violence prevention. She has authored more than 90 peer-reviewed publications and book chapters on injury prevention and violence. Dr. Houry received her MD and MPH degrees from Tulane University and completed her residency training in emergency medicine at Denver Health Medical Center.

    Mark D. Sullivan

    MD, PhD

    Dr. Mark Sullivan received his M.D. and his Ph.D. in Philosophy from Vanderbilt University. After completing an internship in Family Medicine at University of Missouri, he completed a residency in Psychiatry at the University of Washington in 1988. He is now Professor of Psychiatry and Behavioral Sciences as well as Adjunct Professor of Anesthesiology and Pain Medicine and Adjunct Professor of Bioethics and Humanities at the University of Washington. He has served as attending physician in the UW Center for Pain Relief for over 25 years, where he is Co-Director of Behavioral Health Services. He has published over 240 peer-reviewed articles, many on chronic pain. He is currently participating in NIMH, NIDA, CDC, PCORI and VA-funded studies on opioid therapy for chronic pain. He has been chair of the Ethics Committee of the American Pain Society and on the editorial board of Pain. He has a book forthcoming from Oxford University Press titled, The Patient as Agent of Health and Health Care.

    Karol Kaltenbach

    PhD

    Professor of Pediatrics and Professor of Psychiatry and Human Behavior; Director; Maternal Addiction Treatment, Education and Research; Department of Pediatrics, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA Dr. Karol Kaltenbach is the Director of Maternal Addiction Treatment, Education and Research (MATER), a division of the Department of Pediatrics, Jefferson Medical College. MATER includes “Family Center", a comprehensive intensive outpatient treatment program for pregnant and parenting opioid dependent women; “My Sister's Place", a long-term residential treatment program for women and children; and a research component. Family Center has provided the prototype both nationally and internationally for the management of opioid dependency during pregnancy and the treatment of neonatal abstinence. She is a member of the College on Problems of Drug Dependence and has been the Principle Investigator of grants from the National Institute on Drug Abuse (NIDA) and the Center for Substance Abuse Treatment. She is currently a Principal Investigator of the NIDA MOTHER clinical trial comparing the use of buprenorphine and methadone in the treatment of opioid dependence during pregnancy and is a co-investigator of a NIDA funded trial investigating the use of buprenorphine in the treatment of neonatal abstinence syndrome (NAS). Dr. Kaltenbach is an internationally recognized expert in the field of maternal addiction and has published extensively on the management of opioid dependence during pregnancy and neonatal abstinence syndrome (NAS); gender specific treatment for pregnant and parenting substance abusing women; and the effect of prenatal drug exposure on the perinatal and developmental outcome of children. She has lectured throughout the world and has participated in the development of national guidelines for the management of opioid dependent pregnant women and their neonates in Australia and Norway.

    Edwin A. Salsitz (Moderator)

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

  • Opioid Use Disorder: Acute and Long Term Treatment Issues (1.75 CME)

    Contains 6 Component(s), Medical Credits Offered

    Session 2 from The ASAM State of the Art Course in Addiction Medicine contains 4 separate presentations on opioid use disorder.

    Medications for treating various aspects of Opioid Use Disorder include the use of agonists, partial agonists and antagonists. Although medication assisted therapy is recognized as an effective strategy to manage Opioid Use Disorder, the decisions on duration of treatment and tapering strategies receives less attention. Explore these issues and delve into managing Opioid Use Disorder with naltrexone, the selection of appropriate patients for this approach and managing clinical issues that emerge during treatment with antagonists. The use of naloxone for prevention of overdose mortality and implementation of naloxone provision programs for lay persons will also be discussed. The development of an opioid overdose-reversing intranasal formulation of naloxone for use by lay persons is also highlighted.

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

    Adam Bisaga

    MD

    Dr. Adam Bisaga is a Professor of Psychiatry at Columbia University Medical Center, and a Research Scientist at New York State Psychiatric Institute. His research, funded by the NIDA, is focused on development of new medications to treat opioid and other substance use disorders. Dr. Bisaga has been involved in teaching medical professionals and is a co-director of the fellowship in Addiction Psychiatry. He is co-directing the SAMHSA-funded national training and mentoring project “Providers' Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)" to implement treatments for opioid use disorders. Dr. Bisaga is the editor of UN/WHO International Standards for the Treatment of Drug Use Disorders and conducts trainings for addiction practitioners internationally. Dr. Bisaga has also participated in the Congressional hearings “Combatting the Opioid Epidemic" providing an academic perspective, and he is a practicing addiction psychiatrist.

    Philip O. Coffin

    MD, MIA, FACP

    Phillip Coffin, MD, MIA, is a clinician investigator. He is a board-certified, practicing internist and infectious disease specialist, including inpatient and outpatient care. Dr Coffin's research focuses on reducing the medical morbidity of substance use. His active studies include clinical trials and observational studies evaluating pharmacotherapies for substance use disorders and HIV prevention, opioid overdose prevention and naloxone availability, and hepatitis C treatment for persons who inject drugs.

    Phil Skolnick

    PhD, DSc (Hon.)

    Phil Skolnick, Ph.D., D.Sc. (hon.) is the Director, Division of Therapeutics & Medical Consequences, National Institute on Drug Abuse, NIH. Prior to rejoining NIH in 2010, Dr. Skolnick served as Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, Inc. He was a Lilly Research Fellow (Neuroscience) at Lilly Research Laboratories (1997-2000). Dr. Skolnick served as Senior Investigator and Chief, Laboratory of Neuroscience, at the NIH from 1986-1997. He has also served as a Research Professor of Psychiatry at New York University-Langone Medical Center, Research Professor of Psychiatry at the Uniformed Services University of the Health Sciences, Adjunct Professor of Anesthesiology at Johns Hopkins University, and Adjunct Professor of Pharmacology and Toxicology at Indiana University School of Medicine. He received a Ph.D. from the Department of Pharmacology, George Washington University School of Medicine (1972), and served as a Staff Fellow and Senior Staff Fellow at the NIH under Dr. John W. Daly (1972-1977). While at NIDA, he led the team responsible for developing the first FDA-approved formulation of intranasal naloxone (Nasal Narcan®) to treat opiate overdose, supported research on novel methodologies to monitor adherence in clinical trials, and championed the use of biologics to treat addictions. Skolnick also introduced multiple, innovative funding mechanisms specifically targeted towards drug development. His awards and honors include the Experimental Therapeutics Prize from the American Society for Pharmacology and Experimental Therapeutics, an Anna Monika Prize, and the A.E. Bennett Award in Biological Psychiatry. He has twice been awarded the Doctor of Science, honoris causa. Dr. Skolnick has published more than 550 articles and currently serves on the editorial advisory boards of more than half a dozen journals. The Institute of Scientific Information (ISI) has acknowledged his contributions by naming him to the elite group of “Highly Cited” authors.

  • Healthcare Delivery: From ACA to Your Practice (2 CME)

    Contains 6 Component(s), Medical Credits Offered

    Session 3 from The ASAM State of the Art Course in Addiction Medicine contains 4 separate presentations on healthcare delivery.

    Discover CONTINUUMTM, a computer assisted clinical interview and ASAM Criteria decision engine designed to conform to Federal healthcare reform requirements. Understand the benefits of this program on patient flow, quality of care, revenues, staffing burden, prior authorization and staff morale. Focus will involve performance standards for physicians and how physicians can deliver quality health care while meeting the expectations of corporate and government entities. This will involve a description of conflicts created by 42 CFR Part 2 and electronic health records and accompanying rules governing private health information. Examine changes in regulation and law designed to balance quality healthcare delivery with protection of privacy of patients seeking treatment for substance use disorder.

    David Gastfriend

    MD, DFASAM

    David R. Gastfriend, MD, served on the faculty of Harvard Medical School for 25 years, most recently as Director of the Addiction Research Program at Massachusetts General Hospital (MGH). His studies of the Patient Placement Criteria published by the American Society of Addiction Medicine (ASAM) have been supported by the NIH's National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, the U.S. Centers for Disease Control, U.S. state governments, managed care corporations, including Aetna Behavioral Healthcare, and foreign governments, including Belgium, Finland, Iceland, Israel, Norway, Switzerland, and the World Health Organization. The author of over 125 scientific publications, he has served on the Boards and Editorial Boards of a number of societies and journals, including ASAM and the International Society of Addiction Medicine (ISAM). He is co-editor of the leading book on treatment matching in the field, The ASAM Patient Placement Criteria for Substance-Related Disorders and editor of Addiction Treatment Matching. In addition to his role at RecoverySearch, Dr. Gastfriend is also Vice President for Scientific Communications at Alkermes, Inc. (NASDAQ: ALKS) where he is involved in research, education and scientific publication on extended-release naltrexone (VIVITROL®) and the company's efforts in the field of addiction treatment.

    Michael M. Miller

    MD, LFAPA, DFASAM

    Michael M. Miller, MD, DFASAM, LFAPA, is the medical director of the Herrington Recovery Center at Rogers Memorial Hospital in Oconomowoc, Wisconsin. He is a board-certified general psychiatrist and addiction psychiatrist. Dr. Miller has practiced addiction medicine for more than 30 years and is certified in addiction medicine by the American Board of Addiction Medicine. He is a Life Fellow of the American Psychiatric Association (APA) and a Distinguished Fellow of the American Society of Addiction Medicine (ASAM). Dr. Miller is also an at-large director of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation, as well as a past president of ASAM. Dr. Miller has served on many task forces and councils of ASAM and the Wisconsin Medical Society (WMS), was chair of the WMS Commission on Addictive Diseases, and is current Speaker of the WMS House of Delegates and a member of the Society's Board of Directors. He serves as a faculty member for the Addiction Psychiatry Fellowship and the Addiction Medicine Fellowship at the University of Wisconsin School of Medicine and Public Health, where he is a Clinical Adjunct Professor. He also is an assistant clinical professor in the Department of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin. Dr. Miller was named the national physician Clinician of the Year by Addiction Professional magazine in 2011. He was the recipient of The ASAM Award in 2013.. Through 2015, he chaired the Steering Committee of ASAM's Practice Improvement and Performance Measurement Action Group. In June 2014, Dr. Miller was elected by the AMA House of Delegates to a four year term on the AMA Council on Science and Public Health.

    Eric Goplerud

    PhD, MA

    Eric Goplerud is a senior fellow and vice president with NORC at the University of Chicago. Goplerud, who joined NORC in 2011, is a clinical psychologist and an expert on substance abuse treatment and prevention who was previously a senior research professor at George Washington University focusing on behavioral health policy. Prior to working at George Washington University, he held several senior policy leadership positions at the Substance Abuse and Mental Health Services Administration (SAMHSA). Since 2002, Goplerud has directed Ensuring Solutions to Alcohol Problems, a research program at George Washington University supported by grants from the Pew Charitable Trusts, the Robert Wood Johnson Foundation, industry, and various federal agencies. He also directs the Center for Integrated Behavioral Health Policy. Goplerud is immediate past president of ACMHA: the College for Behavioral Health Leadership. His primary work focuses on integration of behavioral health into national health reform, improving access and financing for behavioral health in primary and specialty medicine, and engagement of businesses, health insurers, and employee assistance programs to promote access to effective, affordable behavioral health care. Goplerud has directed foundation, corporate, and government-sponsored projects focused on increasing access to effective, affordable alcohol treatment. In addition, Goplerud chaired the National Quality Forum's Technical Advisory Panel that produced the consensus standards of evidence-based substance use treatment, and he co-chairs the Joint Commission on Accreditation of Health Care Organizations (JCAHO) Technical Advisory Panel that designed and is field testing alcohol and tobacco SBIRT performance measures for all hospital admissions.

  • Guidelines for Treating Substance Use Disorders (1.5 CME)

    Contains 5 Component(s), Medical Credits Offered

    Session 4 from The ASAM State of the Art Course in Addiction Medicine contains 3 separate presentations on guidelines for treating SUD.

    Gain an overview of the development and recommendations of The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Understand initiatives being implemented by the Department of Health and Human Services in response to the nation's opioid overdose crisis. Also explore the national and international guidelines that address treatment needs of women in the perinatal period.

    Kyle M. Kampman

    MD

    Dr. Kyle Kampman graduated from Northwestern University in 1981 and Tulane University School of Medicine in 1985. He interned at the National Naval Medical Center at Bethesda Maryland and served in the United States Navy from 1985 until 1990. He came to the University of Pennsylvania and served as a resident in psychiatry from 1990 until 1993. He then completed a fellowship in Addiction Psychiatry. In 1994 he joined the faculty in the Department of Psychiatry as an assistant professor. He was promoted to associate professor in 2003 and to professor in 2012. Dr. Kampman has had extensive experience in the treatment of alcohol cocaine and opiate dependence. He has conducted a number of trials testing medications for the treatment of cocaine alcohol and opiate dependence and is a recognized authority on the cocaine withdrawal syndrome. In addition to research, he works at the Addiction Recovery Unit of the Philadelphia VA Medical Center where he continues to treat cocaine, alcohol and opiate dependent patients with both medications and psychotherapy.

    Jennifer Fan

    PharmD, JD

    CAPT Jennifer Fan is currently the Special Assistant to the Director of the Center for Substance Abuse Prevention (CSAP) in the Substance Abuse and Mental Health Services Administration (SAMHSA). She is also the Co-lead for SAMHSA's Strategic Initiative: Prescription Drug Abuse Prevention. Prior to her role as Special Assistant, CAPT Fan worked in the Division of Workplace Programs overseeing the Federal Drug-Free Workplace Program and was a Public Health Advisor in SAMHSA's Division of Pharmacologic Therapies in CSAT overseeing the NASPER grants for prescription drug monitoring programs as well as working on SAMHSA's Prescriber Education Courses and the compliance of opioid treatment programs. She has also worked in FDA's Office of Generic Drugs; Office of Drug Safety; and the Division of Drug Marketing, Advertising, and Communications as well as CMS' Part B Reimbursement. CAPT Fan received her PharmD from the University of Maryland and her JD from the University of Baltimore.

    Karol Kaltenbach

    PhD

    Professor of Pediatrics and Professor of Psychiatry and Human Behavior; Director; Maternal Addiction Treatment, Education and Research; Department of Pediatrics, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA Dr. Karol Kaltenbach is the Director of Maternal Addiction Treatment, Education and Research (MATER), a division of the Department of Pediatrics, Jefferson Medical College. MATER includes “Family Center", a comprehensive intensive outpatient treatment program for pregnant and parenting opioid dependent women; “My Sister's Place", a long-term residential treatment program for women and children; and a research component. Family Center has provided the prototype both nationally and internationally for the management of opioid dependency during pregnancy and the treatment of neonatal abstinence. She is a member of the College on Problems of Drug Dependence and has been the Principle Investigator of grants from the National Institute on Drug Abuse (NIDA) and the Center for Substance Abuse Treatment. She is currently a Principal Investigator of the NIDA MOTHER clinical trial comparing the use of buprenorphine and methadone in the treatment of opioid dependence during pregnancy and is a co-investigator of a NIDA funded trial investigating the use of buprenorphine in the treatment of neonatal abstinence syndrome (NAS). Dr. Kaltenbach is an internationally recognized expert in the field of maternal addiction and has published extensively on the management of opioid dependence during pregnancy and neonatal abstinence syndrome (NAS); gender specific treatment for pregnant and parenting substance abusing women; and the effect of prenatal drug exposure on the perinatal and developmental outcome of children. She has lectured throughout the world and has participated in the development of national guidelines for the management of opioid dependent pregnant women and their neonates in Australia and Norway.

    Frank J. Vocci (Moderator)

    PhD

    Frank Vocci, PhD, President and Senior Research Scientist, Friends Research Institute, Baltimore, MD. Following a post-doctoral fellowship in addiction pharmacology at the Medical College of Virginia, Dr. Frank Vocci spent 11 years at the FDA, rising to the level of Chief of the Drug Abuse Staff. At the FDA, he reviewed applications for marketing of medications for analgesic medications and for the treatment of substance abuse disorders. He also participated in domestic and international drug control issues. In 1989, he joined the Medications Development Program at the National Institute on Drug Abuse. He became the Director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC) in 1997 where he was responsible for overseeing research and development activities in medications development for the treatment of addictive disorders. He was also responsible for biomedical research in the medical consequences of drug abuse, primarily AIDS and hepatitis C research. During his tenure, the DPMC collaborated on the development of four addiction drug products that were approved by the FDA. Dr. Vocci has published over 100 articles in neuropharmacology and the treatment of substance abuse and its consequences. In 2001, he received a Meritorious Executive award from President Bush for his management of the NIDA medications development program. Dr. Vocci also received a Distinguished Service Award in 2003 from the College on Problems of Drug Dependence for his contributions to the development of buprenorphine as a treatment for opiate dependence. In 2006 Dr. Vocci received the Vernelle Fox award from the California Society of Addiction Medicine and the FeDerSerD (Italian Addiction Society) award. Dr. Vocci has been a co-editor of the Journal of Addiction Medicine since 2012 and is a past-president of the College on Problems of Drug Dependence.

  • Cannabinoids: Therapeutic Potentials & Medical Consequences (2.25 CME)

    Contains 7 Component(s), Medical Credits Offered

    Session 5 from The ASAM State of the Art Course in Addiction Medicine contains 4 separate presentations on cannabinoids

    Examine several topics in the field of cannabinoids. An update on cannabis legalization will be followed by a presentation on the role of medical caregivers dispensing information on cannabis, its effects and the unwanted effects of cannabinoid products. A discussion of synthetic cannabinoids, new psychoactive substances and the illegal market that has proliferated will follow. Discussion includes the evolving problems associated with this epidemic. For example, synthetic cannabinoids are not detected in conventional drug tests that assay for tetrahydrocannabinol, creating monitoring issues for criminal justice, highway safety and medical personnel treating individuals under the influence of synthetic cannabinoids. The last presentation reviews the current evidence of therapeutic potentials of cannabinoids and discusses efficacy outcome measures for possible clinical indications.

    Gregory C. Bunt

    MD, FASAM

    Dr. Gregory Bunt graduated from NYU School of Medicine in 1983, completed his residency in Psychiatry at the AECOM in 1987, and a Fellowship in Addiction Psychiatry at NYU (1989), and is currently as an Assistant Clinical Professor of Psychiatry at NYU. He is a diplomat of the American Board of Psychiatry and Neurology in Addiction Psychiatry. Dr. Bunt is currently the medical director of Daytop Village and consultant to Daytop International. Dr. Bunt also serves as the President of the New York Society of Addiction Medicine and the President-Elect of the International Society of Addiction Medicine as well. He has authored over a dozen publications, and speaks nationally and internationally on the subject of therapeutic communities.

    R. Jeffrey Goldsmith

    MD, DLFAPA, DFASAM

    Dr. Goldsmith began his addiction medicine career in 1974 as a medical student, learning about the disease of alcoholism as a counselor for one of the Department of Transportation's Alcohol Safety Action Projects. He received his medical training at the University of Cincinnati College of Medicine from 1973-1977 and finished his residency in Psychiatry at UC in 1981.

    Recent Employment history

    In 1994 Dr. Goldsmith joined the VA fulltime. From 1994-2009, he split his time between Dual Diagnosis Services and other duties including all of the psychiatric consultations for the hospital (1994-1997) and research with the Clinical Trials Network (1995-2009). He was an active member of Cincinnati's NIDA research group, and Cincinnati's principal investigator for its pivotal study of buprenorphine/naloxone for opiate addiction. Dr Goldsmith also created an integrated Primary Care Mental Health program with the director of Primary Care, initiated in 2007 and still active.

    Currently Dr. Goldsmith works in the VA Buprenorphine Treatment Clinic.

    Teaching

    In 1994, Dr. Goldsmith developed an ACGME accredited Addiction Psychiatry Fellowship and the following year was funded by the Dept. of Veterans Affairs for a two year Addiction Medicine Fellowship. He holds the title of Professor of Clinical Psychiatry in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati. He was addiction fellowship director from 1989 to 2007 and continues to teach in addiction fellowships: Psychiatry and ABAM.

    ASAM involvement

    Dr. Goldsmith joined ASAM in 1984, became ASAM certified in 1986 and got his CAQ in Addiction Psychiatry in 1994. He has been on the CME committee since then, and was its chair for nine years from 2000-2009. Dr Goldsmith is President of ASAM 2015-2017.

    Robert L. DuPont

    MD, DFASAM

    For more than 40 years, Robert L. DuPont, M.D. has been a leader in drug abuse prevention and treatment. He served as the first Director of the National Institute on Drug Abuse (1973-1978) and as the second White House Drug Chief (1973-1977). From 1968-1970 he was Director of Community Services for the District of Columbia Department of Corrections, heading parole and half-way house services. From 1970-1973, he served as Administrator of the District of Columbia Narcotics Treatment Administration. Following this distinguished public career, in 1978 Dr. DuPont became the founding president of the Institute for Behavior and Health, Inc., a non-profit organization that identifies and promotes new ideas to reduce illegal drug use. He has been Clinical Professor of Psychiatry at the Georgetown University School of Medicine since 1980. 

    A graduate of Emory University, Dr. DuPont received an M.D. degree in 1963 from the Harvard Medical School. He completed his psychiatric training at Harvard and the National Institutes of Health in Bethesda, Maryland. 

    Dr. DuPont is a Life Fellow of the American Society of Addiction Medicine. His activities in ASAM include chairing the forensic science committee from 1995 to 2004, and serving as Co-Chair of the two White Paper writing committees that produced The Role of the Physician in “Medical” Marijuana in 2010 and State-Level Proposals to Legalize Marijuana in 2012. He served as Chair of the writing committee that produced Drug Testing: A White Paper of the American Society of Addiction Medicine in 2013. He is also a Life Fellow of the American Psychiatric Association and was chairman of the Drug Dependence Section of the World Psychiatric Association from 1974 to 1979. In 1989 he became a founding member of the Medical Review Officer Committee of ASAM."

    Jag Khalsa

    PhD, MS

    Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology/medicine, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. E-mail: jk98p@nih.gov

  • Weed in your Workplace: What You Need to Know (2 CME)

    Contains 6 Component(s), Medical Credits Offered

    Session 6 from The ASAM State of the Art Course in Addiction Medicine contains 4 separate presentations on cannabis products.

    SAMHSA's guidance for implementing drug testing programs is utilized to explore the challenges of incorporating testing for synthetic and designer drugs of abuse into regulated testing. The proliferation of types and varieties of cannabis products, their effects on users and potential effects of environmental exposure on non-users will be discussed. Discourse will include the dose effects of cannabis delivered by different routes of administration and whether and to what degree biomarkers can inform cannabis-induced behavioral impairment.

    Ron R. Flegel

    BS, MT(ASCP), MS

    RONALD R. FLEGEL, B.S., MT (ASCP), M.S. Ronald R. Flegel became the Director of the Division of Workplace Program in May of 2012. He initially joined The Division of Workplace Programs, Substance Abuse and Mental Health Services Administration in September of 2004 as the Forensic Toxicologist, following his employment with a nationally recognized laboratory, Quest Diagnostics Nichols Institute. His prior position was with a nationally recognized consulting firm, The Walsh Group, P.A. Prior to this position, he was employed with Quest Diagnostics Incorporated in the Forensic Toxicology Department as Shift Manager/ Section Supervisor in a SAMHSA Certified regulated drug testing laboratory. As a Technologist at Johns Hopkins Hospital, Department of Pathology, he certified and reviewed chemistry and emergency toxicology data. Mr. Flegel recently testified before the Committee on Oversight and Government Reform, Subcommittee on Government Operations on the Federal response to marijuana legalization as it pertains to transportation policy. He has lectured on numerous occasions for professional organizations on topics such as Prescription Drug Abuse, and Programs to Deter Drug Use, Analytical Approaches to Emergency Toxicology. Until he became Director, he had overseen the National Laboratory Certification Program as the Government Project Officer within SAMHSA on areas such as inspection protocols, review of regulatory guidelines, regulatory compliance issues and guidance documents for laboratories. In 1989, he had the honor of receiving the John C. Failing Award for Bench Medical Technologist of the Year. Mr. Flegel received his Bachelor's Degree from Northern Michigan University in biology and medical technology and his Master's Degree from The University of Maryland in Forensic Toxicology. He also completed rotations at the Poison Control Center and Medical Examiner's Office in the state of Maryland as well as his Medical Technology Internship at Hurley Medical Center in the department of pathology.

    John M. Mitchell

    PhD

    Dr. John M. Mitchell is currently a Senior Director in the Center for Forensics Sciences (CFS) at RTI International in Research Triangle Park, North Carolina. Dr. Mitchell serves as the director of the DHHS contract which executes the National Laboratory Certification Program (NLCP). He is responsible for managing all aspects of NLCP laboratory performance testing and Inspecttion activities and direct research efforts in support of testing conducted for Federal workplace programs. His background in forensic toxicology has included experience as Commanding Officer and Scientific Director of the Navy Drug Testing Laboratory in Jacksonville, Florida and Scientific Director of the Norfolk Navy Drug Testing Laboratory, lead researcher at two DOD Research Institutes, and NLCP inspector, He has authored or coauthored over 35 scientific articles in peer reviewed publications and 2 book chapters. The experience he has gained in the development of test methods for drugs of abuse testing and organizational structures for drug testing laboratories and by participation in collaborative research with the National Institute of Drug Abuse and Johns Hopkins University on drug abuse studies has provided him with the tools needed to oversee the technical aspects of the NLCP as it has evolve over the past 23 years.

    Edward J. Cone

    PhD, FABT

    Edward Cone, PhD, is an employee of PinneyAssociates, a consulting firm in Bethesda, MD that provides services to the pharmaceutical and healthcare industry. Dr. Cone also owns and operates ConeChem Research, LLC, Mobile, AL and provices consulting services to government and private industry regarding methods of drug testing. He also has an appointment as adjunct professor at the Johns Hopkins Bayview Medical Center, Baltimore, MD. His major research interests are in drug delivery systems and the disposition and metabolism of drugs of abuse and drug-induced behavioral effects. Dr. Cone's research into the kinetics and dynamics of smoked drugs, effects of environmental exposure to drugs of abuse, and the use of alternative specimens like saliva, sweat and hair for drug testing has been recognized world-wide. Dr. Cone's research has resulted in the publication of over 300 scientific articles on the chemistry of pharmaceuticals and illicit drugs of abuse.

    Ryan G. Vandrey

    PhD

    Ryan Vandrey, PhD is an Associate Professor at the Johns Hopkins University Behavioral Pharmacology Research Unit (BPRU). Dr. Vandrey's research focuses on the behavioral pharmacology of cannabis (marijuana) with a primary focus of controlled laboratory studies with adult research volunteers, but also includes clinical trials, web-based survey research, and natural history studies with patient populations using cannabis/cannabinoids for therapeutic purposes. His work helped characterize the cannabis withdrawal syndrome, has provided novel data about the comparative pharmacokinetics and corresponding pharmacodynamics of cannabinoids across routes of administration, explored medications that are potential adjuncts to behavior therapy to improve rates of abstinence among individuals trying to quit using cannabis, examined the effects of cannabis on sleep, and provides information about the risks and benefits of medicinal use of cannabis/cannabinoids for various health conditions.

    Melinda Campopiano, MD (Moderator)

    Medical Officer, Substance Abuse and Mental Health Services Administration

    Dr. Melinda Campopiano currently serves as Medical Officer for the Center for Substance Abuse Treatment at the Substance Abuse Mental Health Services Administration (SAMHSA). She is a physician Board Certified in Family Medicine with additional credentialing in Addiction Medicine.

    Dr. Campopiano has worked in both primary care and addiction medicine including managing programs and patients using methadone and buprenorphine. Prior to joining SAMHSA, she participated in the development, implementations and evaluation of a curriculum in SBIRT for medical students and residents at the Pennsylvania Department of Health Bureau of Drug and Alcohol Programs.

  • New Issues in Medical Co-Morbidities (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Session 7 from The ASAM State of the Art Course in Addiction Medicine contains 2 separate presentations on medical comorbidities.

    Injection drug users have high rates of co-occurring infectious diseases. The first presentation describes the public health problem of Hepatitis C infection, changing demographics of the infected population and ways to cure the infection in injection drug users. The possibility of reinfection in injection drug users and the challenge it presents, along with diagnosis and management of neurocognitive changes brought on by HIV/HCV co-infection in aging patients with substance use disorders will be discussed.

    David L. Thomas

    MD, MPH

    DAVID L. THOMAS, M.D., M.P.H., is Chief of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. Dr. Thomas is trained in internal medicine and infectious diseases and cares for patients with infectious diseases including chronic viral hepatitis. He also oversees clinical research projects whose aims are focused on understanding the natural history and pathogenesis of hepatitis C virus infection. Liver disease in HIV infected persons is a special area of clinical and research focus. He is the principal investigator on numerous National Institutes of Health grants and the author or co-author of over 200 peer-reviewed publications. Dr. Thomas has served the National Institutes of Health, Centers for Disease Control, and IDSA in multiple capacities has won international recognition for his academic contributions.

    Ajay Bharti

    MD

    Assistant Professor of Medicine, University of California San Diego

    Jag Khalsa (Moderator)

    PhD, MS

    Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology/medicine, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. E-mail: jk98p@nih.gov

  • Updates on Psychiatric Comorbidities (1.5 CME)

    Contains 5 Component(s), Medical Credits Offered

    Session 8 from The ASAM State of the Art Course in Addiction Medicine contains 3 separate presentations on prescription opioids.

    Patients with a substance use disorder have a high prevalence of both lifetime and current psychiatric comorbidities. Analyze the prevalence of PTSD in patients with a substance use disorder, the neurobiology of PTSD and its management by behavioral and pharmacological approaches. Discourse includes the frequency, consequences and treatment of drug and alcohol use in patients with co-occurring bipolar disorder and schizophrenia.

    Emma L. Barrett

    PhD

    Dr. Emma Louise Barrett is a registered psychologist and Visiting Fulbright Scholar in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina, and part-time Research Fellow at the University of New South Wales, Sydney, Australia. She received her Ph.D. in public health and community medicine at the National Drug and Alcohol Research Centre in Sydney and completed a postdoctoral fellowship at the NHMRC Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales. Dr Barrett has conducted a number of studies examining innovative evidence-based treatments for co-occurring mental health and substance use disorders. As part of her Fulbright Scholarship she is currently developing an integrated treatment for adolescents with co-occurring PTSD and substance use disorder. Dr Barrett has received a number of academic awards in recognition of her research excellence, including the 2015 University of New South Wales Rising Star Award.

    Thomas R. Kosten

    MD

    Thomas R. Kosten, M.D. is Waggoner Chair and Professor of Psychiatry, Pharmacology, Immunology and Neuroscience at Baylor College of Medicine and former professor and chief of Psychiatry at Yale University and VA Connecticut. He is past director of the VA national Substance Use Disorders Quality Enhancement Research Initiative. He is founder of the Division of Substance Abuse at Baylor and Yale and directed both NIH Medications Development Centers for substance abuse and now directs the DoD national consortium for Pharmacotherapy of Alcoholism and Substance Abuse. He has been supported by a Research Scientist Award from the NIH since 1987 and has served on national and international review groups for medications development in substance abuse. He has been a Congressional Fellow in the House of Representatives and a visiting Professor in Germany, Spain, Greece, China, Russai and Canada. He is founding vice chair for Added Qualifications in Addiction Psychiatry of the American Board of Psychiatry and Neurology. He is a distinguished life fellow in the American Psychiatric Association and fellow of the American College of Neuropsychopharmacology, past president of the American Academy of Addiction Psychiatry, and past president of the College on Problems of Drug Dependence. He has received several international awards for clinical research, and is editor of two major journals in substance abuse and been on the American Journal of Psychiatry board. Recent work includes serving on several National Academy of Sciences committees on substance abuse. From his studies in substance dependence, post traumatic stress disorder, pharmacogenetics and neuroimaging he has published over 750 papers, books and reviews. His medication contributions include a cocaine vaccine, immunotherapy for stimulants, buprenorphine for opioid dependence, disulfiram for cocaine dependence and pharmacogenetics of opioid and cocaine dependence.

    E. Sherwood Brown

    MD, PhD

    E. Sherwood Brown, M.D., Ph.D., is Professor with Tenure, Vice Chairman for Clinical Research, Chief of the Division of Clinical Neuroscience, and the Aradine S. Ard Chair in Brain Science in the Department of Psychiatry at The University of Texas Southwestern Medical Center, Dallas, Texas. He received B.A. and Ph.D. degrees in chemistry from Texas Christian University. He received an M.D. degree from The University of Texas Medical School at Houston, and completed a psychiatry residency, on the research track, at The University of Texas Southwestern Medical Center followed by a research fellowship. He is board certified in both psychiatry and the subspecialty of psychosomatic medicine. For many years he has conducted research on people with bipolar disorder and substance use disorders, and has received numerous grants from the National Institutes of Health and private foundations for research in this area. He has conducted the majority of randomized, controlled trials in people with bipolar disorder and substance use disorders conducted to date. He is a member of the American College of Neuropsychopharmacology, Society for Biological Psychiatry, Research Society on Alcoholism, Academy of Psychosomatic Medicine and American Psychiatric Association. He serves on seven journal editorial boards including Biological Psychiatry and the Journal of Affective Disorders, and is co-Editor-in-Chief of the Journal of Dual Diagnosis. In 2002 he was co-recipient of the Gerald L. Klerman Award for clinical research from the National Alliance for Research in Schizophrenia and Depression.

    Jag Khalsa (Moderator)

    PhD, MS

    Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology/medicine, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. E-mail: jk98p@nih.gov

  • Brain Imaging & Addiction: New Findings (2.25 CME)

    Contains 6 Component(s), Medical Credits Offered

    Session 9 from The ASAM State of the Art Course in Addiction Medicine contains 3 separate presentations on prescription opioids.

    Magnetic Resonance Imaging (MRI) and functional MRI (fMRI) are discussed regarding their applications to phenomena in addiction medicine. Following a description of the fMRI technique, imaging data will be presented showing brain changes associated with cognitive and affective mechanisms as an individual transitions to addiction. Links between the genetics of addiction and imaging data will be analyzed. Imaging correlates of smoking cues in smokers and their predictive validity to smoking cessation will be described. Discussion covers functional, structural and neurochemical evaluations of regions involved in cue-reactivity and craving. Discourse will also include neural substrates of cannabis abstinence and the implication of these findings to treatment development.

    Elliot A. Stein

    PhD

    Dr. Elliot Stein is Chief of the Neuroimaging Research Branch at the National Institute on Drug Abuse Intramural Research Program (NIDA-IRP). Prior to coming to NIDA in 2002, he was Professor of Psychiatry at the Medical College of Wisconsin (MCW), where he was also Professor in the Departments of Pharmacology, Neurobiology and the Biophysics Research Institute. He received his PhD from the University of Maryland School of Medicine in neurophysiology and completed a post-doctoral fellowship at the California Institute of Technology with James Olds, a pioneer in brain reward systems. His research program employs multimodal MR imaging to define those neuronal systems and circuits mediating the actions of abused drugs, to determine CNS sites and mechanisms responsible for mediating drug craving and reinforcement, and how drugs interact with specific cognitive processes to alter behavior. Most recently he has been examining the influence of various genetic polymorphisms on imaging biomarkers of addiction.

    Amy C. Janes

    PhD

    Dr. Janes directs the Functional Integration of Addiction Research Laboratory at Harvard Medical School's McLean Hospital. She received her PhD in 2007 from Boston University where her work focused on molecular mechanisms of cocaine dependence. After a term as a postdoctoral fellow at McLean Hospital, she was awarded a K01 to gain skills in clinical neuroimaging of nicotine dependence. She currently holds an R01 research grant to continue her line of inquiry into how reactivity to drug cues contribute to addiction. Broadly, her current work centers on using neuroimaging to meet three main goals: 1) identifying individual differences in vulnerability for developing and maintaining addictive disorders, 2) evaluating brain changes following treatment, and 3) understanding how cognitive, affective, and psychiatric disorders contribute to addiction. A primary focus of her lab is determining the impact of smoking-related cues on nicotine dependence and clarifying the neurobiological processes associated with heightened cue reactivity.

    Sarah W. Yip

    PhD

    Sarah W. Yip, PhD is an Associate Research Scientist in Psychiatry at Yale University's School of Medicince. Dr. Yip received her PhD in Psychiatry from the University of Oxford, where she received training in multimodal neuroimaging. Her work uses neuropsychiatric research methods to identify the biological mechanisms of psychiatric disorders with the long-term aim of improving treatments.

    Frank J. Vocci (Moderator)

    PhD

    Frank Vocci, PhD, President and Senior Research Scientist, Friends Research Institute, Baltimore, MD. Following a post-doctoral fellowship in addiction pharmacology at the Medical College of Virginia, Dr. Frank Vocci spent 11 years at the FDA, rising to the level of Chief of the Drug Abuse Staff. At the FDA, he reviewed applications for marketing of medications for analgesic medications and for the treatment of substance abuse disorders. He also participated in domestic and international drug control issues. In 1989, he joined the Medications Development Program at the National Institute on Drug Abuse. He became the Director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC) in 1997 where he was responsible for overseeing research and development activities in medications development for the treatment of addictive disorders. He was also responsible for biomedical research in the medical consequences of drug abuse, primarily AIDS and hepatitis C research. During his tenure, the DPMC collaborated on the development of four addiction drug products that were approved by the FDA. Dr. Vocci has published over 100 articles in neuropharmacology and the treatment of substance abuse and its consequences. In 2001, he received a Meritorious Executive award from President Bush for his management of the NIDA medications development program. Dr. Vocci also received a Distinguished Service Award in 2003 from the College on Problems of Drug Dependence for his contributions to the development of buprenorphine as a treatment for opiate dependence. In 2006 Dr. Vocci received the Vernelle Fox award from the California Society of Addiction Medicine and the FeDerSerD (Italian Addiction Society) award. Dr. Vocci has been a co-editor of the Journal of Addiction Medicine since 2012 and is a past-president of the College on Problems of Drug Dependence.

At the conclusion of the course, participants should be able to:

  1. Review the latest epidemiology and prescribing guidelines for opioids and treatment approaches for Opioid Use Disorder
  2. Discuss the latest trends in marijuana legislation, policy, testing, synthetic cannabinoids and implications for practice
  3. Review best practice guidelines for management of Opioid Use Disorder and management of the pregnant substance user
  4. Understand changes in healthcare delivery resulting from the Affordable Care Act and electronic health records implementation
  5. Review clinical management of medical and psychiatric comorbidities seen in patients with substance use disorders
  6. Describe brain imaging technologies and how these are changing the view of the addicted brain
  7. Describe new pharmacotherapies for alcohol and opioid use disorders

Who should attend:

  • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
  • Physicians and other health care professionals who seek an advanced level of knowledge of addiction medicine
  • Primary care clinicians who manage patients with addiction in their practice
  • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine